Adlai Nortye Group vs Rani Therapeutics Holdings
Adlai Nortye Group is the larger business, with $5.0m of revenue in fiscal 2025 against $1.6m for Rani Therapeutics Holdings (3.1 times as much). Rani Therapeutics Holdings grew faster (58.9% against 0.0%). Adlai Nortye Group kept more of each dollar of sales as profit: a net margin of -710.6% against -1817.1%.
| Latest fiscal year | Adlai Nortye GroupANL, 2025 | Rani Therapeutics HoldingsRANI, 2025 |
|---|---|---|
| Revenue | $5.0m | $1.6m |
| Revenue growth | 0.0% | 58.9% |
| Net income | −$35.5m | −$29.7m |
| Operating margin | -714.0% | -2346.0% |
| Net margin | -710.6% | -1817.1% |
| Return on equity | -106.5% | -169.6% |
| Free cash flow | −$33.6m | −$18.8m |
| Cash | $8.1m | $18.6m |
| Total debt | $24.6m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 69 |
| Market value | $304m | $104m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 7 sales | 2 buys, 1 sales |